Q2 Earnings Forecast for ResMed Issued By William Blair

ResMed Inc. (NYSE:RMD) – Equities researchers at William Blair issued their Q2 2025 earnings per share estimates for shares of ResMed in a research report issued to clients and investors on Wednesday, December 11th. William Blair analyst M. Andrew anticipates that the medical equipment provider will post earnings of $2.29 per share for the quarter. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the previous year, the firm earned $1.64 earnings per share. ResMed’s quarterly revenue was up 11.1% on a year-over-year basis.

Several other analysts also recently commented on RMD. KeyCorp increased their target price on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus assumed coverage on shares of ResMed in a research note on Friday. They issued a “hold” rating and a $250.00 price objective for the company. Wolfe Research reissued an “underperform” rating and set a $180.00 target price on shares of ResMed in a research report on Wednesday, September 18th. Royal Bank of Canada upped their target price on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a report on Friday, October 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $227.91.

ResMed Price Performance

Shares of NYSE:RMD opened at $238.52 on Monday. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The stock has a market cap of $35.01 billion, a PE ratio of 31.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.68. The stock’s fifty day simple moving average is $242.75 and its two-hundred day simple moving average is $227.74. ResMed has a 1-year low of $164.12 and a 1-year high of $260.49.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th were paid a $0.53 dividend. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. ResMed’s payout ratio is presently 28.08%.

Insider Activity

In related news, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the transaction, the insider now directly owns 21,718 shares in the company, valued at approximately $5,279,428.62. The trade was a 22.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $237.20, for a total value of $474,400.00. Following the sale, the director now owns 85,204 shares in the company, valued at approximately $20,210,388.80. This represents a 2.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,725 shares of company stock valued at $11,253,448 in the last 90 days. Insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On ResMed

Several hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. boosted its stake in ResMed by 1.9% in the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 47 shares during the period. Ascent Group LLC lifted its holdings in shares of ResMed by 1.7% in the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider’s stock worth $714,000 after buying an additional 48 shares in the last quarter. SkyView Investment Advisors LLC boosted its position in shares of ResMed by 2.0% in the third quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider’s stock valued at $637,000 after acquiring an additional 51 shares during the period. Inspire Advisors LLC grew its stake in ResMed by 1.9% during the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock valued at $586,000 after acquiring an additional 56 shares in the last quarter. Finally, Concurrent Investment Advisors LLC grew its stake in ResMed by 3.1% during the third quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 57 shares in the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.